Related Experiment Videos
Acquired hypercoagulable state in renal transplant recipients
1Department of Nephrology and Renal Transplantation, Saint-Jacques University Hospital, 25000, Besançon, France. akazory@chu-besancon.fr
Thrombosis and Haemostasis
|March 27, 2004
Summary
Renal transplant recipients face increased clotting risks due to multifactorial causes. This review details transplant-specific hypercoagulable factors, including immunosuppressants and post-transplant erythrocytosis.
Area of Science:
- Nephrology
- Transplantation Medicine
- Hematology
Background:
- Stable renal transplant recipients exhibit a chronic hypercoagulable state.
- This heightened risk of thromboembolism is multifactorial, encompassing general population risks and transplant-specific factors.
Purpose of the Study:
- To review the clinical aspects and controversies of key hypercoagulable factors in renal transplant recipients.
- To discuss both established and emerging factors contributing to thrombosis risk post-transplantation.
Main Methods:
- Literature review of clinical aspects and controversies.
- Discussion of established and recent topics related to hypercoagulability in renal transplant recipients.
Main Results:
- Identified key factors include immunosuppressive agents, antiphospholipid antibodies, hyperhomocysteinemia, pre-transplant dialysis modality, and post-transplant erythrocytosis.
- Emerging factors such as hypercysteinemia, recurrent proteinuria, and acute CMV infection are also discussed.
Conclusions:
- Understanding these multifactorial risks is crucial for managing thromboembolic complications in renal transplant patients.
- Further research into the specific mechanisms and management of these factors is warranted.